Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1348362 · FYE Aug 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.40Day −25.23%Mkt cap $13M1Y −56.7%Off 52W high −74.4%Vol (1Y) 108.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,363 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.7% of sh out |
| Days to cover2.8d |
| 13F net flow (QoQ)−1.84% |
| Top-10 13F concentration91.3% |
| Next report (est.)2026-10-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$194,000 |
| Earnings (TTM)-$7.7M |
| ROE−215.9% |
| Net margin−1686.0% |
| Sales growth 3Y40.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−35.8% |
| 1Y−56.7% |
| 3Y−52.5% |
| 5Y−93.6% |
| Since incept. (ann.)−40.1% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)108.6% |
| Ann. volatility (3Y)102.7% |
| Sharpe (1Y)−0.18 |
| Sharpe (3Y)0.27 |
| Max drawdown (1Y)−74.1% |
| Max drawdown (3Y)−93.7% |
| Beta (3Y vs SPY)0.55 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Invenomic Capital Management LP | 442,301 | $344,995 | 1.78% | −6.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 294,157 | $229,471 | 1.18% | +33.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 222,293 | $173,389 | 0.89% | new |
| TORONTO DOMINION BANK | 140,013 | $109,279 | 0.56% | +0.0% |
| VANGUARD FIDUCIARY TRUST CO | 94,166 | $73,449 | 0.38% | new |
| UBS Group AG | 52,708 | $41,112 | 0.21% | −85.4% |
| STATE STREET CORP | 39,301 | $30,655 | 0.16% | +0.0% |
| BlackRock, Inc. | 27,445 | $21,407 | 0.11% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-05-31 | 2026-07-13 | −$0.08 | — | $0 | −100.0% |
| 2026-02-28 | 2026-04-13 | −$0.06 | — | $20,000 | −88.5% |
| 2025-11-30 | 2026-01-13 | −$0.07 | — | $0 | −100.0% |
| 2025-08-31 | 2025-11-28 | — | — | $174,000 | +107.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Intellectual Property Licensing 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
